Rectify Pharma

Thanks to BiotechTV for speaking with our CEO, Rajesh Devraj, about?how we are advancing positive functional modulators (#PFMs) to restore & enhance membrane protein function and?potentially addressing pathophysiology?of #PrimarySclerosingCholangitis. #TLM24?

At American Association for the Study of Liver Diseases (AASLD)’s #TLM24, we're showcasing new data on the potential of positive functional modulators (#PFMs) to restore and enhance membrane protein function in hepatobiliary diseases and introducing a new translational model of cholangitis and cholestasis. Learn more here: https://lnkd.in/ewT2KfBY

We are proud to support the ALD Connect 2024 Annual Meeting & Patient Learning Academy and were grateful for the opportunity to share data demonstrating reduction of toxic VLCFA levels in patient fibroblasts for our ABCD1/2 PFM program. Find more details here: https://lnkd.in/eMV2_JtM

Join us for our Virtual R&D Event on November 21! Meet our team and learn more about how we are advancing an orally available ABCB4/BSEP targeted PFM for the treatment of PSC to the clinic. Find out more details here: https://bit.ly/4hNNEqQ

?? We’re excited to unveil our new website and share our progress towards our mission to rectify membrane protein function and restore hope for patients with serious diseases. Check it out here: https://bit.ly/3UKr3Sd

Our CEO, Rajesh Devraj, discusses key trends disrupting the pharma industry featured in the latest edition of The Medicine Maker. Read the full article to hear his insights on the role of advanced discovery platforms in drug development: https://lnkd.in/gRAb9vAa

In case you missed it, we recently announced positive functional modulator RTY-694 as development candidate for primary sclerosing cholangitis (#PSC). Discover how our #PFM's differentiated mechanism of action has potential to improve bile composition and flow: https://bit.ly/48jIezp

Our CEO, Rajesh Devraj, met with Darren Incorvaia from Fierce Biotech to discuss the first development candidate to emerge from our breakthrough proprietary positive functional modulator (#PFM) platform. At Rectify, we’re developing small molecule therapies to restore or enhance membrane protein function. Check out the full article to learn more: https://bit.ly/3YyNKei

We shared new translational data for our cardio-renal-metabolic program at the International Symposium on Cardiovascular Calcification (iSCCa) Meeting First International Symposium on Cardiovascular Calcification showing potential for a ABCC6 positive functional modulator (#PFM) to decrease vascular calcification and improve renal function. Learn more about our work here: https://bit.ly/3NBouxL

Today, we announced the selection of our lead ABCB4/BSEP dual-targeted positive functional modulator (#PFM) for treatment of primary sclerosing cholangitis (PSC) and a broad range of hepatobiliary diseases by improving bile composition and enhancing bile flow. We look forward to advancing RTY-694 a novel, differentiated, oral small molecule to first-in-human clinical trials for PSC. Read our press release to learn more: https://bit.ly/48jIezp